Viridian Therapeutics, Inc. DE (VRDN)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue - related party | 75 | 72 | 86 | |
| Research and development (including related party expenses of and 4,528 during the three and six months ended june30, 2025, respectively, and 2,551 and 3,212 during the three and six months ended june30, 2024, respectively) | 86,626 | 76,835 | 69,158 | |
| Research and development (including related party expenses of and 4,528 during the three and six months ended june30, 2025, respectively, and 2,551 and 3,212 during the three and six months ended june30, 2024, respectively)-Paragon Therapeutics | - | - | - | |
| General and administrative | 20,216 | 17,103 | 14,408 | |
| Total operating expenses | 106,842 | 93,938 | 83,566 | |
| Loss from operations | -106,767 | -93,866 | -83,480 | |
| Interest and other expense | 514 | 586 | 1,004 | |
| Interest and other income | 6,546 | 7,540 | 7,795 | |
| Other income, net | 6,032 | 6,954 | 6,791 | |
| Net loss | -100,735 | -86,912 | -76,689 | |
| Change in unrealized (loss) gain on investments | - | 255 | 1,475 | |
| Change in unrealized gain (loss) on investments | -176 | - | - | |
| Total other comprehensive income (loss) | -176 | 255 | 1,475 | |
| Total comprehensive loss | -100,911 | -86,657 | -75,214 | |
| Basic eps | - | -0.87 | -1.15 | |
| Diluted eps | - | -0.87 | -1.15 | |
| Basic average shares | - | 81,344,134 | 66,420,063 | |
| Diluted average shares | - | 81,344,134 | 66,420,063 | |